Department of Medicine, Section of Hematology-Oncology, University of Chicago, 5841 South Maryland Avenue, Room E-212A, MC2115, Chicago, IL 60637, USA. Electronic address: https://twitter.com/Anand_88_Patel.
Section of Hematology/Oncology, Lymphoma Program, Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, USA.
Hematol Oncol Clin North Am. 2020 Aug;34(4):647-662. doi: 10.1016/j.hoc.2020.02.002. Epub 2020 May 6.
Follicular lymphoma comprises approximately 20-30% of all cases of B-cell lymphomas. Median survival has improved significantly in the modern era. Prognostic factors include histologic grade, cytogenetics, molecular mutations, the tumor microenvironment, and tumor burden. Clinical prognostic indices are available and increasingly incorporate genetic information. Prognostic factors also arise during the course of treatment. Early progression within 24 months of initial chemoimmunotherapy is an adverse prognostic marker of inferior survival. Other high-risk populations include those with double refractory disease or those with high risk of transformation to diffuse large B-cell lymphoma.
滤泡性淋巴瘤约占所有 B 细胞淋巴瘤的 20-30%。在现代,中位生存期已显著改善。预后因素包括组织学分级、细胞遗传学、分子突变、肿瘤微环境和肿瘤负荷。目前已有临床预后指标,并越来越多地纳入遗传信息。在治疗过程中也会出现预后因素。初始化疗免疫治疗后 24 个月内早期进展是生存预后不良的不良预后标志物。其他高危人群包括双重难治性疾病或转化为弥漫性大 B 细胞淋巴瘤风险较高的患者。